Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 1.00 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.70 |
| ▸ | JAK1 | P23458 | 6/20 | 0.68 |
| ▸ | JAK2 | O60674 | 4/20 | 0.68 |
| ▸ | JAK3 | P52333 | 8/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1818948 | 0.93 | HPGDS (0.88) | HPGDSIRAK4JAK1JAK2JAK3 | |
| SCHEMBL31034574 | 0.89 | HPGDS (0.79) | HPGDSIRAK4JAK1JAK2JAK3 | |
| SCHEMBL31034708 | 0.89 | HPGDS (0.79) | HPGDSIRAK4JAK1JAK2JAK3 | |
| SCHEMBL20708124 | 0.88 | HPGDS (0.78) | HPGDSIRAK4JAK1JAK2JAK3 | |
| SCHEMBL30945085 | 0.88 | HPGDS (0.78) | HPGDSIRAK4JAK1JAK2JAK3 | |
| SCHEMBL31034653 | 0.88 | HPGDS (0.78) | HPGDSIRAK4JAK1JAK2JAK3 | |
| SCHEMBL1815412 | 0.86 | HPGDS (0.76) | HPGDSIRAK4JAK1JAK2JAK3 | |
| SCHEMBL16765136 | 0.86 | HPGDS (0.74) | HPGDSIRAK4JAK1JAK2JAK3 | |
| SCHEMBL18419023 | 0.86 | HPGDS (0.74) | HPGDSIRAK4JAK1JAK2JAK3 | |
| SCHEMBL16765135 | 0.86 | HPGDS (0.74) | HPGDSIRAK4JAK1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617267-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617267-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617267-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2501236-B1 | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer | PLEXXIKON INC (US) | 2017-03-29 | — | — | EP | disclosed |
| EP-2501236-B1 | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer | PLEXXIKON INC (US) | 2017-03-29 | — | — | EP | disclosed |
| CN-105906631-A | Compounds and methods for kinase modulation, and indications therefor | 普莱希科公司 | 2016-08-31 | — | — | CN | disclosed |
| US-20140288070-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-09-25 | — | — | US | disclosed |
| US-20140288070-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-09-25 | — | — | US | disclosed |
| US-20140288070-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-09-25 | — | — | US | disclosed |
| US-8673928-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673928-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-03-18 | — | — | US | disclosed |
| CN-102740698-A | Compounds and methods for kinase modulation and indications therefor | PLEXXIKON INC | 2012-10-17 | — | — | CN | disclosed |
| EP-2501236-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON INC. | 2011-06-23 | — | — | US | disclosed |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON INC. | 2011-06-23 | — | — | US | disclosed |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON INC. | 2011-06-23 | — | — | US | disclosed |
| WO-2011063159-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063159-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-7435739-B2 | Substituted pyrrolopyrimidines useful in the treatment of cancer | CHEN JINSHAN | 2008-10-14 | — | — | US | disclosed |
| US-20050130994-A1 | Pyrrolopyre compounds useful in treatment of cancer | PFIZER INC | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130994-A1 | Pyrrolopyre compounds useful in treatment of cancer | TP53, CCNT1, CCNE1 | HPGDS 513/4885IRAK4 2261/4885JAK1 376/4885 |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, KRAS, RAF1 | HPGDS 566/4885IRAK4 1140/4885JAK1 210/4885 |
| US-20140288070-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, KRAS, RAF1 | HPGDS 566/4885IRAK4 1140/4885JAK1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.